ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Questionnaire
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Account
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Press
August 6, 2024
09 Dec 2020

Acarix AB meddelar att den sista patienten i Dan-NICAD II studien har inkluderats

Pressmeddelande Malmö, 9 december 2020 Acarix AB meddelar att den sista patienten i Dan-NICAD II studien har inkluderats Efter att ...
Continue reading
author-avatar acarix
Press
August 6, 2024
26 Nov 2020

FDA identifies exclusive code for the CADScor®

Press release (MAR)Malmö, Sweden, November 26, 2020 FDA identifies exclusive code for the CADScor® After yesterday’s announcement and...
Continue reading
author-avatar acarix
Press
August 6, 2024
26 Nov 2020

FDA identifierar unik kod för CADScor®

Pressmeddelande (MAR) Malmö, 26 november 2020 FDA identifierar unik kod för CADScor® Efter gårdagens meddelande och ytterligare analy...
Continue reading
author-avatar acarix
Press
August 6, 2024
25 Nov 2020

Acarix erhåller marknadsgodkännande för CADScor® System för försäljning på den amerikanska marknaden

Pressmeddelande (MAR) Malmö, Sverige, 25 november 2020 Acarix erhåller marknadsgodkännande för CADScor®  System för försäljning på den...
Continue reading
author-avatar acarix
Press
August 6, 2024
25 Nov 2020

Acarix receives US market approval for the CADScor® System

Press release (MAR)Malmö, Sweden November 25, 2020 Acarix receives US market approval for the CADScor® System Acarix AB (publ) today...
Continue reading
author-avatar acarix
Press
August 6, 2024
18 Nov 2020

Positiva resultat från Acarix-jämförelseanalys presenterades på den ledande hälsoekonomiska konferensen ISPOR

Pressmeddelande Malmö, Sverige, 18 november 2020 Positiva resultat från Acarix-jämförelseanalys presenterades på den ledande hälsoeko...
Continue reading
author-avatar acarix
Press
August 6, 2024
18 Nov 2020

Positive results from Acarix study presented at ISPOR, a leading health economics conference

Press releaseMalmö, Sweden November 18, 2020 Positive results from Acarix study presented at ISPOR, a leading health economics confere...
Continue reading
author-avatar acarix
Press
August 6, 2024
15 Oct 2020

Acarix byter Certified Advisor till Redeye

Pressmeddelande Malmö, Sverige, 15 oktober 2020 Acarix byter Certified Advisor till Redeye Acarix AB (publ) Acarix AB meddelar...
Continue reading
author-avatar acarix
Press
August 6, 2024
15 Oct 2020

Acarix changes Certified Advisor to Redeye

  Press release Malmö, Sweden October 15, 2020 Acarix changes Certified Advisor to Redeye Acarix AB (publ) announces today that ...
Continue reading
author-avatar acarix
Press
August 6, 2024
03 Sep 2020

Acarix går vidare med de tyska myndigheterna

Pressmeddelande Malmö, Sverige, 3 september 2020 Acarix går vidare med de tyska myndigheterna Acarix AB (publ) meddelade idag ...
Continue reading
author-avatar acarix
Press
August 6, 2024
03 Sep 2020

Acarix progresses with the German authorities

Press releaseMalmö, Sweden September 3, 2020 Acarix progresses with the German authorities Acarix AB (publ) today announced that...
Continue reading
author-avatar acarix
Press
August 6, 2024
02 Sep 2020

Acarix två största aktieägare överlåter teckningsrätter i företrädesemissionen vederlagsfritt – förlänger teckningsperioden

Pressmeddelande Malmö, 2 september 2020 Acarix två största aktieägare överlåter teckningsrätter i företrädesemissionen vederlagsfritt ...
Continue reading
  • «
  • ‹
  • 14
  • 15
  • 16
  • 17
  • 18
  • ›
  • »
Acarix AB
Jungmansgatan 12
211 19 Malmö
SE
[email protected]

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • Press
  • Events
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V5

  • Products
    • Background
    • What is Coronary Artery Disease
    • Diagnosing CAD
    • About the product
    • The Cadscor System
    • How Does it Work
  • Resources
    • Testimonial
    • HCP Stories
    • Patients Stories
    • References
    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Support
    • Training
    • Faq
    • Reimbursement
    • Physician Locator
    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
    • About Acarix
    • Leadership
    • Join The Team
    • Get in touch
    • Contact Us
    • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.